Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Study shows how the microbiome shapes lung cancer immunotherapy outcomes (opens in a new tab)

news-medical.net · 2026-09-09

Short answerEvidenceSource

Short answer

Not supported

Not supported.

The study does not answer the story's main claims.

  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

The study doesn't address any of the story's claims. We found the paper, but it doesn't report the details the story leads with.

  • 5 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredA research team from Peking University People's Hospital in Beijing published a comprehensive review in Cancer Biology & Medicine on the microbiome's role in lung cancer immunotherapy.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the paper is a systematic/comprehensive review of microbiome influences on lung cancer immunotherapy. However, the supplied profile does not verify the author team’s institutional affiliation, Beijing location, or journal venue. Those bibliographic details may be true, but they are not verifiable from the abstract-depth evidence supplied here.

1

Study evidence

The microbiome has emerged as a promising predictor of immunotherapy outcomes in lung cancer.

“The influence of the microbiome on lung cancer immunotherapy was systematically and comprehensively reviewed.”
Claim 2 of 5Not coveredThe review says the microbiome operates as an interconnected ecosystem spanning the oral cavity, airways, lungs and gut, with each site contributing distinct predictive information.View evidenceHide evidence

Why this verdict

The profile supports broad multi-site and site-specific framing, including future directions such as multi-site integrated biomarkers and site-specific interventions. But the abstract-depth evidence does not specify an interconnected ecosystem spanning the oral cavity, airways, lungs, and gut, nor does it establish that each site contributes distinct predictive information. This level of anatomical and predictive detail is not verifiable at the supplied depth.

1

Study evidence

The microbiome has emerged as a promising predictor of immunotherapy outcomes in lung cancer.

“The influence of the microbiome on lung cancer immunotherapy was systematically and comprehensively reviewed.”
2

Study evidence

The microbiome is identified as a promising predictor of immunotherapy outcomes in lung cancer.

“discussed strategies for microbiome-targeted interventions.”
Claim 3 of 5Not coveredThe article says AKK-positive patients showed higher objective response rates and 12-month survival of 59% versus 35% in AKK-negative patients, and that moderate Akkermansia muciniphila abundance appeared best while levels above 5% may reduce benefit.View evidenceHide evidence

As stated12-month survival of 59% versus 35%; above 5% may diminish benefit

Why this verdict

The abstract-level profile supports only the general point that distinctive microbiome profiles correlate with ICI treatment effectiveness. It explicitly lacks specific taxa, quantitative associations, effect sizes, or performance metrics. Therefore, the AKK/Akkermansia-specific objective response, 12-month survival comparison of 59% versus 35%, and abundance-threshold claim above 5% cannot be verified from the supplied abstract-depth evidence.

1

Study evidence

The microbiome has emerged as a promising predictor of immunotherapy outcomes in lung cancer.

“The influence of the microbiome on lung cancer immunotherapy was systematically and comprehensively reviewed.”
2

Study evidence

The microbiome is presented as a promising predictor of lung cancer immunotherapy outcomes, with the review emphasizing its potential to explain why 60%–80% of patients respond poorly to ICIs.

“We investigated the core mechanisms of the interactions between the microbiome and the tumor microenvironment,”
Claim 4 of 5Not coveredMicrobiome-based prediction models reportedly achieved accuracy above 80% and outperformed PD-L1 expression alone, and integrating multiple body sites improved prediction further.View evidenceHide evidence

As statedaccuracy above 80%

Why this verdict

The profile supports the broad idea that the microbiome is a promising predictor of ICI outcomes and that multi-site integrated biomarker approaches are discussed as future directions. But the abstract-depth evidence states that quantitative predictive performance metrics are not provided, and it does not mention accuracy above 80%, comparison with PD-L1 expression alone, or demonstrated improvement from integrating multiple body sites. These details are not verifiable at this depth.

1

Study evidence

The microbiome has emerged as a promising predictor of immunotherapy outcomes in lung cancer.

“The influence of the microbiome on lung cancer immunotherapy was systematically and comprehensively reviewed.”
2

Study evidence

The microbiome is identified as a promising predictor of immunotherapy outcomes in lung cancer.

“discussed strategies for microbiome-targeted interventions.”
Claim 5 of 5Not coveredThe authors say interventions including probiotic supplementation, fecal microbiota transplantation, dietary modification and engineered bacteria are being investigated to improve immunotherapy efficacy and reduce immune-related adverse events, but most current evidence remains associative rather than causal.View evidenceHide evidence

Why this verdict

The profile supports that microbiome-targeted intervention strategies are discussed conceptually and that current evidence requires further validation rather than being established by new primary trial data. However, the abstract-depth evidence does not enumerate probiotic supplementation, fecal microbiota transplantation, dietary modification, or engineered bacteria, and it does not specifically mention reducing immune-related adverse events. The caveated, non-causal framing is consistent with the profile, but the intervention list and irAE component are not verifiable at this depth.

1

Study evidence

The microbiome is identified as a promising predictor of immunotherapy outcomes in lung cancer.

“discussed strategies for microbiome-targeted interventions.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The review assesses microbial metabolites as candidate predictive or functional biomarkers for ICI response.

    Microbial metabolites are a material element in the abstract-level profile, but the story presentation does not mention metabolites or metabolite-based biomarkers.

    From Systematic and comprehensive literature review; narrative review / mechanistic synthesis; Narrative synthesis / review

  • The supplied abstract-depth profile does not provide search strategy, inclusion/exclusion criteria, study-selection details, quality assessment methods, specific taxa, quantitative effect sizes, or predictive performance metrics.

    These are limitations of what can be assessed from the abstract-level profile. The story includes several precise taxa- and model-performance claims, but it does not acknowledge that such details are not available in the abstract-depth evidence supplied here.

    From Systematic and comprehensive literature review; Narrative synthesis / review

5 things the story did carry across
  • The paper is a systematic/comprehensive secondary review synthesizing evidence on microbiome influences on lung cancer immunotherapy and ICI outcomes.
  • The review presents the microbiome as a promising predictor of lung cancer immunotherapy outcomes and reports that distinctive microbiome profiles correlate with treatment effectiveness.
  • The review discusses mechanisms linking the microbiome, microbial signals, the tumor microenvironment, and anti-tumor immunity.
  • The review discusses microbiome-targeted intervention strategies and future research directions, including site-specific interventions and multi-site integrated biomarker approaches.
  • The paper’s abstract indicates methodological limitations in the field and the need for future research before clinical translation.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataSynthesize and evaluate evidence that the microbiome predicts and modulates immune checkpoint inhibitor (ICI) outcomes in lung cancer, including distinctive microbiome profiles associated with treatment effectiveness.Systematic and comprehensive literature reviewExpand

In plain English

Systematic, comprehensive literature review synthesizing clinical and preclinical evidence that the microbiome both predicts and modulates immune checkpoint inhibitor (ICI) outcomes in lung cancer. The review reports that distinctive microbiome profiles correlate with ICI treatment effectiveness, examines core microbiome–tumor microenvironment mechanisms, evaluates microbial metabolites as candidate predictive biomarkers, and discusses microbiome-targeted intervention strategies and methodological limitations with recommendations for future research.

Key findings

  • The microbiome has emerged as a promising predictor of immunotherapy outcomes in lung cancer.
  • Distinctive microbiome profiles among patients with lung cancer correlate with ICI treatment effectiveness.
“The influence of the microbiome on lung cancer immunotherapy was systematically and comprehensively reviewed.”
What this piece can’t prove
  • The authors note existing limitations in research methodology in the field and call for targeted future research directions.

3 further details could not be confirmed from the summary.

2secondary dataSummarize and appraise proposed mechanisms linking the microbiome (and microbial metabolites) to the lung tumor microenvironment and anti-tumor immunity, including metabolite-based biomarker concepts.narrative review / mechanistic synthesisExpand

In plain English

Narrative review synthesizing proposed mechanisms by which the microbiome influences the lung tumor microenvironment (TME) and anti-tumor immunity, and evaluating microbial metabolites as candidate predictive/functional biomarkers for lung cancer immunotherapy. The authors present an interpretive mechanistic framework linking patient-associated microbiome profiles and microbial metabolites to variation in immune checkpoint inhibitor (ICI) outcomes, and discuss microbiome-targeted intervention strategies and methodological gaps that limit current biomarker translation.

Key findings

  • The microbiome is presented as a promising predictor of lung cancer immunotherapy outcomes, with the review emphasizing its potential to explain why 60%–80% of patients respond poorly to ICIs.
  • Distinctive microbiome profiles among patients with lung cancer are discussed and linked by the authors to correlations with treatment effectiveness.
“We investigated the core mechanisms of the interactions between the microbiome and the tumor microenvironment,”
What this piece can’t prove
  • This unit is a narrative, interpretive review rather than a report of new primary experimental data.
  • The abstract indicates that the review evaluated limitations in current research methodology but does not specify those limitations in detail.

2 further details could not be confirmed from the summary.

3secondary dataDiscuss microbiome-targeted intervention strategies to improve lung cancer immunotherapy and outline methodological limitations and future research directions (e.g., multi-site integrated biomarkers, site-specific interventions).Narrative synthesis / reviewExpand

In plain English

This paper is a comprehensive review examining how the microbiome influences lung cancer immunotherapy and discussing microbiome-targeted intervention strategies and methodological limitations. It synthesizes evidence that the microbiome is a promising predictor of immune checkpoint inhibitor (ICI) outcomes, describes distinctive microbiome profiles correlated with treatment effectiveness, evaluates microbial metabolites as potential predictive biomarkers, and outlines intervention strategies and a research agenda (including multi-site integrated biomarkers, site-specific interventions, metabolite-based functional biomarkers, and lung cancer–specific microbiome considerations).

Key findings

  • The microbiome is identified as a promising predictor of immunotherapy outcomes in lung cancer.
  • Distinctive microbiome profiles among patients with lung cancer are correlated with treatment effectiveness.
“discussed strategies for microbiome-targeted interventions.”
What this piece can’t prove
  • The abstract indicates that current limitations in research methodology were evaluated, but does not specify which methodological weaknesses were identified (e.g., heterogeneity in sampling, lack of longitudinal data, small sample sizes).
  • The abstract does not present quantitative effect estimates or trial-level evidence for the effectiveness of proposed microbiome-targeted interventions.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Cancer Immuno Perspectives · 2025 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.